Found 86 clinical trials
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Background People with rare cancers often have limited treatment options. The biology of rare cancers is not well understood. Researchers want to find better treatments for these cancers. They want to test 2 drugs that, taken separately, have helped people with non-rare cancers. They want to see if these drugs …
- 0 views
- 19 Feb, 2024
PSMA-specific CAR-T Cell Therapy
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of PSMA-specific CAR-T cell therapy in patients with PSMA positive tumor. Another goal of the study is to learn more about the function of the PSMA CAR-T cells and their persistency in the patients.
- 0 views
- 19 Feb, 2024
Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours
This is a phase I, open-label study to assess the safety, tolerability, pharmacokinetics(PK) and anti-tumour activity of adavosertib in Japanese patients with advanced solid tumours. This study consists of 2 cohorts, Cohort1 and Cohort2. At least 3, or up to 6, evaluable Japanese patients with advanced solid tumours will be …
- 0 views
- 19 Feb, 2024
Nivolumab Ipilimumab and Chemoradiation in Treating Patients With Locally Advanced Pancreatic Cancer.
Pancreatic ductal adenocarcinoma (PDAC) remains a dreadful disease due to its often advanced stage at diagnosis and poor sensitivity to chemotherapy. A locally unresectable tumor (locally advanced pancreatic cancer (LAPC)) is present in 30% of the cases and is defined as a surgically unresectable tumor encasing the adjacent arteries [celiac …
- 0 views
- 19 Feb, 2024
NBE-002 in Patients With Advanced Solid Tumors
This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of NBE-002, a novel anti-ROR1 antibody-drug conjugate, in patients with advanced solid tumors.
- 0 views
- 19 Feb, 2024
A Study of SGN-B6A in Advanced Solid Tumors
It will also study whether SGN-B6A works to treat solid tumors. The study will have two parts. Part A of the study will find out how much SGN-B6A should be given to participants. Part B will use the dose found in Part A to find out how safe SGN-B6A is …
- 0 views
- 19 Feb, 2024
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Eligibility Adults age 18 and older with pancreatic cancer, breast cancer, or a solid tumor that has not been cured by standard therapies. Also, children age 12-17 with a solid tumor (other than a muscle tumor) with no standard therapy options.
- 0 views
- 19 Feb, 2024
A Study of SY 5609 a Selective CDK7 Inhibitor in Advanced Solid Tumors
This is a dose escalation study and will be the first to administer SY-5609 alone to humans with select advanced solid tumors and in combination with Fulvestrant to patients with HR positive, HER2-negative breast cancer.
- 0 views
- 19 Feb, 2024
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer
The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of BPI-1178 in subjects with advanced solid tumor, as well as the subjects with advanced hormone receptor-positive(HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer.
- 0 views
- 19 Feb, 2024
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors
Giving avelumab together with M6620 may help to control DDR deficient metastatic or unresectable solid tumors.
- 0 views
- 19 Feb, 2024